Bromperidol decanoate (depot) for schizophrenia

Cochrane Database of Systematic Reviews

Volumn 2012, Issue 11, 2012, Pages

  Purgato, Marianna ^a   Adams, Clive E ^b  

^a UNIVERSITY OF VERONA   (Italy)

^b INSTITUTE OF MENTAL HEALTH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BROMPERIDOL DECANOATE; DRUG DERIVATIVE; HALOPERIDOL; NEUROLEPTIC AGENT;

DELAYED RELEASE FORMULATION; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; HALOPERIDOL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA;

EID: 80055080821     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD001719.pub4     Document Type: Article

References (100)

1. McLaren S, Cookson JC, Silverstone JT. A comparative trial of bromperidol decanoate and fluphenazine decanoate in chronic schizophrenia. Annual General Meeting of the British Association for Psychopharmacology. Cambridge, England. July 15-18,1990. 1990.
2. McLaren S, Cookson JC, Silverstone JT. Bromperidol decanoate: a comparative study in chronic schizophrenia. 8th World Congress of Psychiatry; Athens, Greece. October 12-19, 1989.
3. McLaren S, Cookson JC, Silverstone T. Positive and negative symptoms, depression and social disability in chronic schizophrenia: a comparative trial of bromperidol and fluphenazine decanoates. International Clinical Psychopharmacology 1992;7:67-72.
4. Casacchia M, Di Michele V, Volonte MV, Rossi A. Bromperidol decanoate versus fluphenazine decanoate in schizophrenia. 8th World Congress of Psychiatry. Athens, Greece. October 12-19, 1989.
5. Rossi A, Di Michele VD, Volonte MV, Casacchia M. Therapeutic evaluation of bromperidol decanoate in schizophrenia - a double-blind comparison vs. fluphenazine decanoate. Rivista Sperimentale di Freniatria e Medicina Legale delle Alienazioni Mentali 1990;114:1379-86.
6. Rossi P, Chini C, Casale A, Fusi A, Madonna M, Monaci C, Carta I. Action of bromperidol decanoate in the treatment of negative symptoms of schizophrenia - comparison with haloperidol decanoate [Azione del bromperidolo decanoato nel trattamento dei sintomi negativi della schizofrenia - confronto con l'aloperidolo decanoato]. Rivista di Psichiatria 1992;27:265-70.
7. Bellini L, Smeraldi E, Virzi A, Aguglia E. Bromperidol decanoate versus placebo in residual schizophrenia. 8th World Congress of Psychiatry. Athens, Greece. October 12-19, 1989.
8. Smeraldi E, Brancato V, Bellini L, Ronchi P, Volonte MV, Virzi A, Aguglia E. Bromperidol decanoate versus placebo in treating schizophrenia in the residual phase. New Trends in Experimental and Clinical Psychiatry 1990;6:187-98.
9. Bernardi F, Bocchetta A, Del Zompo M, Volonte MV, Corsini GU. Efficacia terapeutica e tollerabilita del bromperidolo decanoato in pazienti psicotici gia in trattamento con aloperidolo o clorpromazina. Rivista di Psichiatria 1992;27(6):271-5.
10. Boeykens DHJ, Tan BK, Nuijten S. 6-month study of bromperidol decanoate in chronic psychotic patients. 14th CINP Congress. Florence, Italy. June 19-23, 1984.
11. Brannen JO, McEvoy JP, Wilson WH, Petrie WM, Ban TA, Berney SA, Schaffer JD. A double-blind comparison of bromperidol and haloperidol in newly admitted schizophrenic patients. Pharmacopsychiatria 1981;14:139-40.
12. Bures E, Poldinger W. Introductory words to the exchange of results on the clinical effects of bromperidol. Results of open and double blind research [Einleitende Worte zum Austausch der Erfahrungen uber die klinische Wirkung von Bromperidol. Mitteilung uber eigene Ergebnisse im offenen und Doppelblindversuch]. International Pharmacopsychiatry 1978;13(1):45-52.
13. Denijs EL. Clinical evaluation of bromperidol versus haloperidol in psychotic patients. International Pharmacopsychiatry 1980;15:309-17.
14. Fukahori M, Inanaga K, Suetsugu M. Clinical evaluation of sultopride hydrochloride on outpatients with schizophrenia. Japanese Pharmacology and Therapeutics 1995;23:267-80.
15. Germana B, Rapisarda V. Clinical therapeutic experience with bromperidol - a double blind and open study [Esperienze clinico terapeutiche con bromperidolo - prova in doppio cieco e in chiaro]. Rivista di Psichiatria 1990;25:233-5.
16. Gould S, Sethna E, Burns B, Kanakaratnam G, Leslie N, Goodhead D, Moss M, Watt JS. Maintenance therapy of schizophrenia with a novel depot neuroleptic bromperidol decanoate. 3rd World Congress of Biological Psychiatry. Stockholm, Sweden. June 28-July 3, 1981.
17. Gould S, El Sobky A, El Assra A, Hajioff J, Blain P, Wiles D. Relationship between plasma drug concentrations and clinical response after treatment with bromperidol or fluphenazine decanoate. 13th CINP Congress. Jerusalem, Israel. June 20-25, 1982.
18. Hucker H. The use of bromperidol in an open study [Bericht uber die Anwendung von Bromperidol im offenen Versuch]. International Pharmacopsychiatry 1978;13(1):53-61.
19. Hyugano H. The clinical psychopharmacological efficacy of bromperidol for schizophrenia comparison with haloperidol by the single-blind cross-over method. Shinryo to Shinyaku 1986;21(7):1296-306.
20. Itoh H. A comparison of the clinical effects of bromperidol, a new butyrophenone derivative, and haloperidol on schizophrenia using a double-blind technique. Psychopharmacology Bulletin 1985;21:120-2.
21. Kaumeier S, Haase HJ, Schwarz H, Gundel A, Linde OK, Maetz H, Scheel R, Stripf A, Stripf L. Neuroleptic potency of bromperidol [Neuroleptische Potenz von Bromperidol]. International Pharmacopsychiatry 1978;13(1):41-4.
22. Kodama H, Sarai K, Nakahara T. The clinical efficacy of bromperidol for schizophrenia: comparison with haloperidol by the double-blind method. Igaku to Yakugaku 1984;12(1):296-86.
23. Kokasa H, Matsunaga K, Nakamura J. The comparative study of bromperidol and clocapramine for schizophrenia by the double-blind method. Rinsho To Kenkyu 1984;61(11):3721-364.
24. Kudo Y, Ichimaru S, Kawakita Y. A double blind comparison of bromperidol and clocapramine on schizophrenia. Rinsho Seishin Igaku (Japanese Journal of Clinical Psychiatry) 1984;13(10):1283-301.
25. Levi Minzi A, Laviani M. Valutazione dell'efficacia e della tollerabilita del trattamento a lungo termine con bromperidolo decanoato nei disturbi psicotici. Minerva Psichiatrica 1992;33(1):51-5.
26. Malfroid M, Hens L, Roosen P, Dom R. Double-blind evaluation of bromperidol versus haloperidol treatment in chronic psychotic patients. Acta Psychiatrica Belgica 1978;78:147-54.
27. Mauri M, Cassano GB, Canova L, Cocconcelli C, et al. Schizophrenic disorder in active phase: Double-blind study between bromperidol and haloperidol [Disturbo schizofrenico in fase attiva: studio in doppia cecita tra Bromperidolo e Aloperidolo]. Giornale di Neuropsicofarmacologia 1994;16:187-93.
28. Mihara K, Suzuki A, Kondo T, Nagashima U, Ono S, Otani K, Kaneko S. No relationship between Taq1 a polymorphism of dopamine D(2) receptor gene and extrapyramidal adverse effects of selective dopamine D(2) antagonists, bromperidol, and nemonapride in schizophrenia: a preliminary study. American Journal of Medical Genetics 2000;96(3):422-4.
29. Mihara K, Kondo T, Suzuki A, Yasui N, Ono S, Otani K, Kaneko S. No relationship between - 141 C Ins/del polymorphism in the promoter region of dopamine D2 receptor and extrapyramidal adverse effects of selective dopamine D2 antagonist in schizophrenic patients: a preliminary study. Psychiatry Research 2001;1:33-8.
30. Hanssens L, L'Italien G, Loze JY, Marcus RN, Pans M, Kerselaers W. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). BMC psychiatry 2008;8:95. [PUBMED: 19102734]
31. Millet B. A multicenter, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients (Schizophrenia Trial of Aripiprazole - STAR). http://www.clinicaltrials.gov 2005.
32. Nishizono M, Matsuki K. Clinical effects of bromperidol on schizophrenia. Kyushu Shinkei Seishin Igaku Kyushu Neuro-psychiatry 1984;30:373-82. Awaits translation.
33. Onodera I, Ito K, Ito K. The double-blind comparative study of bromperidol and haloperidol in the treatment of schizophrenic inpatients. Kiso to Rinsho 1984;18(7):3349-71.
34. Otani K, Ishida M, Yasui N, Kondo T, Mihara K, Suzuki A, Kaneko S, Inoue Y, Shibata M, Ikeda K. No effect of the anticholinergic drugs trihexyphenidyl and biperiden on the plasma concentrations of bromperidol and its reduced metabolite. Therapeutic Drug Monitoring 1997;19:165-8.
35. Parent M, Toussaint C, Gilson H. Long-term treatment of chronic psychotics with bromperidol decanoate: clinical and pharmacokinetic evaluation. Current Therapeutic Research 1983;34(1):1-6.
36. Poldinger W. Clinical experiences in an open and a double-blind trial. Acta Psychiatrica Belgica 1978;78:96-101.
37. Poldinger W, Bures E, Haage H. Double-blind study with two butyrophenone derivatives: bromperidol vs. haloperidol. International Pharmacopsychiatry 1977;12:184-92.
38. Psaras MS, Paterakis P, Manafi TH, et al. Therapeutic evaluation of bromperidol in schizophrenia - double-blind comparison with chlorpromazine in chronic patients and open administration in schizophrenics with acute symptomatology. Current Therapeutic Research - Clinical and Experimental 1984;36:1089-97.
39. Saito M, Yasui-Furukori N, Nakagami T, Furukori H, Ishida M, Tanaka O, Mihara K, Suzuki A, Otani K, Kondo T, Kaneko S. Comparison of risperidone and dopamine selective inhibitors in acutely exacerbated schizophrenic patients. International Journal of Neuropsychopharmacology 2008;11(suppl1):159.
40. Scapicchio PL, Bassi M, Biasci G, Bietti C, et al. Clinical study comparing 2 different therapeutic regimens (morning vs evening administration) of bromperidol in the treatment of schizophrenia [Studio clinico di confronto tra due diversi schemi terapeutici (somministrazione mattutina o somministrazione serale) di bromperidolo nel disturbo schizofrenico]. Giornale di Neuropsicofarmacologia 1993;15:38-44.
41. Smeraldi E, Cocconcelli C, Canova L, Faravelli C, Marchetti FP, Mariani G, Rapisarda V. Bromperidol decanoate in the residual phase of schizophrenia [Bromperidolo decanoato nel disturbo schizofrenico in fase residua]. Minerva Psichiatrica 1996;37(1):39-44.
42. Spina E, De Domenico P, Bonanzinga M, Amendola DAgostino MA, Gitto C, Di Rosa AE, Caputi AP. A double-blind comparative study of bromperidol versus haloperidol in schizophrenic patients. New Trends in Experimental and Clinical Psychiatry 1992;8:67-71.
43. Suarez Richards M, Lopez Romera A, Amoretti T. Follow-up of nine schizophrenic patients treated during 52 weeks with bromperidol decanoate. 14th CINP Congress. Florence, Italy. June 19-23, 1984.
44. Suzuki A, Otani K, Ishida M, Yasui N, Kondo T, Mihara K, Kaneko S, Inoue Y, Shibata M, Ikeda K. Increased plasma concentrations of bromperidol and its reduced metabolite with levomepromazine, but not with thioridazine. Theraputic Drug Monitoring 1997;19:261-4.
45. Woggon B. Effects and side-effects of bromperidol in comparison with other antipsychotic drugs. Acta Psychiatrica Belgica 1978;78:155-72.
46. Woggon B, Angst J. Double-blind comparison of bromperidol and perphenazine. International Pharmacopsychiatry 1978;13:165-76.
47. Yamagami S, Hirayama E, Mui K, Okuno M, Kioka T, Soma T, Ohno K. A single-blind comparison of bromperidol and sulpiride in hospitalized schizophrenics. Acta Psychiatrica Belgica 1993;93:236-44.
48. Zhao G. Health education of families of schizophrenic patients: the impact of emotional disorder [translated by Google Translate] [[In Mandarin]]. Modern Clinical Nursing 2008;7(4):4-5, 27.
49. Aaes-Jorgensen A. Pharmacokinetics of oral and depot neuroleptics - clinical relevance. Symposium Espo. Feb 1, 1985. 1985.
50. Abhijnhan A, Adams CE, David A, Ozbilen M. Depot fluspirilene for schizophrenia. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD001718.pub2]
51. Adams CE, Fenton MK, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. British Journal of Psychiatry 2001;179:290-9.
52. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200. [DBD020600]
53. Andreasen NC. Negative symptoms in schizophrenia. Archives of General Psychiatry 1982;39:784-8.
54. Andreasen NC. The Scale for the Assessment of Positive Symptoms (SAPS). Univ. of Iowa, 1984.
55. Barnes TRE, Curson DA. Long term depot antipsychotics. A risk benefit assessment. Drug Safety 1994;10(6):464-79.
56. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF. Improving the quality of randomized controlled trials. The CONSORT statement. JAMA 1996;276:637-9.
57. Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
58. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, Boutitie F, Nony P, Haugh M, Mignot G. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie 1999;54(4):405-11. [PUBMED: 10667106]
59. Clarke M, Oxman AD. Cochrane Reviewers' Handbook 4.20 [updated March 2003, available in Cochrane Library]. Oxford, UK: Update Software, 2003.
60. David AS, Cutting JC. The Neuropsychology of Schizophrenia. Hove, E.Sussex: Lawrence Erlbaum Associates, 1994.
61. David A, Adams CE, Eisenbruch M, Quraishi S, Rathbone J. Depot fluphenazine decanoate and enanthate for schizophrenia. Cochrane Database of Systematic Reviews 2005, Issue 1. [DOI: 10.1002/14651858.CD000307]
62. Davis JM, Matalon L, Watanabe MD, Blake L, Matalon L. Depot antipsychotic drugs. Place in therapy. Drugs 1994;47(5):741-73.
63. Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape town. Cape Town: The Cochrane Collaboration, 2000.
64. Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623-9.
65. Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
66. Egger M, Davey G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
67. Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
68. Fleischhacker WW. Second-generation antipsychotic long-acting injections: systematic review. British Journal of Psychiatry 2009;52:S29-36.
69. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(1):7-10.
70. Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
71. Guy W. ECDEU Assessment manual for psychopharmacology. DHEW publication No (ADM). Rockville, MD: National Institute of Mental Health, 1976:124-585.
72. Hamann J, Mendel R, Heres S, Leucht S, Kissling W. How much more effective do depot antipsychotics have to be compared to oral antipsychotics before they are prescribed?. European Neuropsychopharmacology 2010;20(4):276-9.
73. Hamilton M. A rating scale for depression. Journal of Neurology Neurosurgery and Psychiatry 1960;23:56-62.
74. Heres S, Hamann J, Kissling W, Leucht S. Attitudes of psychiatrists toward antipsychotic depot medication. Journal of Clinical Psychiatry 2006;67(12):1948-53.
75. Heres S, Schmitz FS, Leucht S, Pajonk FG. The attitude of patients towards antipsychotic depot treatment. International Clinical Psychopharmacology 2007;22(5):275-82.
76. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
77. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
78. Jablensky A. The 100-year epidemiology of schizophrenia. Schizophrenia Research 1997;28:111-25.
79. Kane JM, Marder SR. Psychopharmacologic treatment of schizophrenia. Schizophrenia Bulletin 1993;19:287-302.
80. Kane JM, Aguglia E, Carlo Altamura A, Guiterrez JLA, Brunello N, Fleischhacker WW, Gaebel W, Gerlach J, Guelfi JD, Kissling W, Lapierre YD, Lindstrom E, Mendlewicz J, Racagni G, Carulla LS, Schooler NR. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology 1998;8:55-66.
81. Kay SR, Opler LA, Fiszbein A. Positive and negative syndrome scale (PANSS) manual. Positive and negative syndrome scale (PANSS) manual. North Tonawanda, NY: Multi-Health Systems, 1986.
82. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale scores. British Journal of Psychiatry 2005;187:366-71. [PUBMED: 16199797]
83. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2-3):231-8. [PUBMED: 15982856]
84. Leucht S, Engel RR, Bauml J, Davis JM. Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin 2007;33(1):183-91. [PUBMED: 16905632]
85. Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot antipsychotic drugs for schizophrenia - a critical systematic review and meta-analysis of randomised long-term trials. Schizophrenia Research 2011;127(1-3):83-92.
86. Marshall M, Lockwood A, Bradley C, Adams CE, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
87. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352:609-13.
88. Moher D, Altman D, Schulz KF. The CONSORT statement: Revised recommendations for improving the Quality of Reports Parallel-Group Randomized Trials. JAMA 2001;285:1987-91.
89. Mueser KT, McGurk SR. Schizophrenia. Lancet 2004;363:2063-72.
90. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799-812.
91. Patel MX, Haddad PM, Chaudhry IB, McLoughlin S, Husain N, David AS. Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years. Journal of Psychopharmacology 2010;24(10):1473-82.
92. Schulz KF, Chalmers I, Grimes DA, Altman DG. Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals. JAMA 1994;272:125-8.
93. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials. Journal of Clinical Epidemiology 2010;63(8):834-40.
94. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359-83.
95. Simon G, Wagner E, Vonkorff M. Cost-effectiveness comparisons using 'real world' randomized trials: the case of new antidepressant drugs. Journal of Clinical Epidemiology 1995;48:363-73.
96. Someya T, Inaba T, Tyndale RF, Tang SW, Takahashi S. Conversion of bromperidol to reduced bromperidol in human liver. Neuropsychopharmacology 1991;5(3):177-82.
97. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1-75.
98. West JC, Wilk JE, Olfson M, Rae DS, Marcus S, Narrow WE, Pincus HA, Regier DA. Patterns and quality of treatment for patients with schizophrenia in routine psychiatric practice. Psychiatric Services 2005;56(3):283-91.
99. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.
100. Adams CE, David A, Quraishi SN. Depot bromperidol decanoate for schizophrenia. Cochrane Database of Systematic Reviews 2004, Issue 3. [DOI: 10.1002/14651858.CD001719]